Glucotoxicity is a major mediator of β-cell dysfunction derived from prolonged hyperglycemia. A better understanding of glucotoxicity and preservation of β-cell mass are urgently needed. Carbohydrate response element binding protein (ChREBP) is a glucose-responsive, lipogenic transcription factor with two splice isoforms, ChREBPα and ChREBPβ. We previously showed ChREBPβ is induced by glucose and is required for glucose-stimulated β-cell proliferation in both rodent and human β-cells. In addition, we identified ChREBPβ as a marker for hyperglycemia in β-cells, with its nuclear expression reflecting the progression and severity of the diabetic state. Here, we demonstrate that β-cell death due to glucolipotoxicity (20 mM glucose + 1 mM palmitate) can be prevented by silencing ChREBPβ (6.5±3.1% TUNEL+/Insulin+ in ChREBPβ knock-out islets compared with 47.2±13.6% in control islets, N=7) , most likely via inhibition of lipogenesis and prevention of ceramide-mediated β-cell death. Furthermore, we generated mice with β-cell specific overexpression of ChREBPβ. These mice exhibited increased non-fasting blood glucose levels, impaired glucose tolerance and a marked decrease in β-cell mass, all in a gene dose-dependent manner (OE of one or two alleles of ChREBPβ, N=5) . ChREBPβ overexpression in human beta cells also mimicked glucotoxicity (93.6±3.1% TUNEL+/Insulin+, N=3) . Importantly, we show that ChREBPβ-mediated rodent and human β-cell death was rescued by co-expression with ChREBPα, or by pharmacological activation of Nrf2, a downstream effector of ChREBPα (6.6±1.9 and 2.8±0.9%, respectively, TUNEL+/Insulin+, N=3) . Altogether, our data demonstrate that ChREBPβ is a marker and a causative effector of glucotoxicity, and that downregulating ChREBPβ levels or upregulating ChREBPα levels or its downstream effector (NRF2) rescues β-cells from glucotoxicity. These results position ChREBPβ as a therapeutic target for the prevention of β-cell loss in T2D, an important unmet need in diabetes research.


L.S.Katz: None. G.Brill: None. M.A.Herman: Research Support; Eli Lilly and Company. A.Garcia-ocana: Consultant; Sun Pharmaceutical Industries Ltd. D.Scott: None.


NIH, R01DK130300NIH, R01DK114338NIH, R01DK108905

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at